Company intelligence / Profile preview

Shanghai BDgene Therapeutics Co., Ltd.

Ownership: Private
Development stage: Preclinical

Overview

BDgene has advanced its lead candidate BD111 for HSV-1 keratitis to Phase 3 clinical trials in China as of 2023. BD111 has completed 3 human clinical trials and received orphan drug designation from the US FDA in June 2022. The company is also developing BD-211 for Beta-Thalassemia which is in Phase 1, and has several preclinical programs.

Therapeutic areas: Infectious DiseasesOphthalmologyNeurologyHematology
Modalities: Gene editingGene therapymRNA deliveryLentiviral vectorsHematopoietic stem cell therapy
Industry: Biotech

Drug pipeline

11 assets

BD111

10 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Shanghai BDgene Therapeutics Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai BDgene Therapeutics Co., Ltd..

Explore the full profile